© The Canadian Journal of Urology™; 19(Supplement 1); October 2012
References
1.
Schappert SM. Ambulatory care visits to physican offices,
hospital outpatient departments, and emergency departments:
United States, 1997. Vital Health Stat 13. 199;(143):i-iv,1-39.
2.
Foxman B, Brown P. Epidemiology of urinary tract infections:
transmission and risk factors, incidence, and costs.
Infect Dis Clin
North Am
2003;17(2):227-241.
3.
Foxman B. Epidemiology of urinary tract infections: incidence,
morbidity, and economic costs.
Dis Mon
2003;49(2):53-70.
47
Diagnosis and management of simple and complicated urinary tract infections (UTIs)
is lacking.
7
One preventative strategy that has been
greatly debated has been the effectiveness of cranberry-
containing products for the prevention of UTIs. Arecent
systematic review and meta-analysis of randomized
controlled trials of cranberry-containing products
concluded that their use is associated with a protective
effect—the risk ratio for cranberryusers versus nonusers
was 0.62 (95% confidence interval [CI], 0.49 to 0.80).
45
The investigators cautioned that the results should be
interpreted in the context of substantial heterogeneity
across trials. The use of cranberry-containing products
provides an alternative (or addition) to the use of
low-dose antimicrobial prophylaxis for women with
recurrent UTIs.
Summary
UTIs remain a common clinical problem in both the
community and healthcare-associated settings. Each
patient should be carefully assessed to ensure that
a correct diagnosis is made and that antimicrobial
therapy is appropriately prescribed—defined as using
a clinically indicated agent in the correct dose and
route of administration, for the correct duration—
for symptomatic patients, and avoided for most
asymptomatic patients. This should help stem the
growing tide of antimicrobial resistance and allow for
the continued use of simpler, less expensive agents.
Continued surveillance andmonitoring of antimicrobial
resistance rates will be critical to help formulate and
update future treatment recommendations for all
categories of patients with UTIs.
Disclosure
Dr. Tony Mazzulli has been a member of scientific
advisoryboards,receivedresearchgrantsand/orspeaker
honoraria from the following commercial entities:
Bayer Healthcare, Pfizer, Merck Frosst, Luminex, and
Gilead.
4.
HootonTM,BradleySF,CardenasDDetal.Diagnosis,prevention,
and treatment of catheter-associated urinary tract infection in
adults: 2009 international clinical practice guidelines from the
infectious diseases society of America.
Clin Infect Dis
2012;50(5):
625-663.
5.
LinK, FajardoK. Screening for asymptomatic bacteriuria in adults:
evidence for the U.S. preventive services task force reaffirmation
recommendation statement.
Ann InternMed
2008;49(1):
W-20-W-24.
6.
Johansen TE, Botto H, Cek M et al. Critical review of current
definitions of urinary tract infections and proposal of an EAU/
ESIU classification system.
Int J Antimicrob Agents
2011;38
Suppl:
64-70.
7.
Hooton TM. Uncomplicated urinary tract infection.
NEngl J Med
2012;366(11):1028-1037.
8.
HardingGk, Zhanel GG,NicoleLE, CheangM.ManitobaDiabetes
Urinary Tract Infection Study Group. Antimicrobial treatment in
diabeticwomenwithasymptomatic bacteriuria.
NEngl JMed
2002;
347(20):1576-1583.
9.
Smaill F, Vazquez JC. Antibiotics for asymptomatic bacteriuria
in pregnancy.
Cochrane Database Syst Rev
2007:
CD000490.
10.
Nicolle LE. Asymptomatic bacteriuria: review and discussion
of the IDSAguidelines.
Int J Antimicrob Agents
2006;28(
Suppl 1):
S42-S48.
11.
Little P, Moore MV, Turner S et al. Effectiveness of five
different approaches in management of urinary tract infection:
randomized controlled trial.
BMJ
2010;340:
c199.
12.
McIsaacWJ, LowDE, BiringerA, Pimlott N, EvansM, Glazier R.
The impact of empirical management of acute cystitis on
unnecessary antibiotic use.
Arch InternMed
2002;162(5):600-605.
13.
McIsaac WJ, Moineddin R, Ross S. Validation of a decision aid
to assist physicians in reducing unnecessary antibiotic drug use
for acute cystitis.
Arch Intern Med
2007;167(20):2201-2206.
14.
GuptaK,HootonTM,NaberKGet al. International clinical practice
guidelines for the treatment of acute uncomplicated cystitis and
pyelonephritis inwomen:A2010update by the InfectiousDiseases
SocietyofAmerica and theEuropeanSociety forMicrobiology and
Infectious Diseases.
Clin Infect Dis
2011;53:
e103-e120.
15.
Ikaheimo R, SiitonenA, Heiskanen T. Recurrence of urinary tract
infection in a primary care setting analysis of a 1 year follow up
of 179 women.
Clin Infect Dis
1996;22(1):91-99.
16.
Brown PD, Freeman A, Foxman B. Prevalence and predictos of
trimethoprim-sulfamethoxazole resistance among uropathogenic
Escherichia coli isolates in Michigan.
Clin Infect Dis
2002;34(8):
1061-1066.
17.
Metlay JP, StromBL,AschDA. Prior antimicrobial drug exposure:
a risk factor for trimethoprim-sulfamethoxazole-resistant urinary
tract infections.
J Antimicrob Chemother
2003;51(4):963-970.
18.
Zhanel GG, Karlowsky JA, DeCorby M et al. Prevalence of
antimicrobial-resistant pathogens in Canadian hospitals: results
of the Canadian Ward Surveillance Study (CANWARD 2007).
Can J Infect Dis Med Microbiol
2009;20(
Suppl A):9A-19A.
19.
Gupta K, Scholes D,Stamm WE. Increasing prevalence of
antimicrobial resistance among uropathogens causing acute
uncomplicated cystitis in women.
JAMA
1999;281(8):736-738.
20.
Hoban DJ, Nicolle LE, Hawser S, Bouchillona S, Badal R.
Antimicrobial susceptibility of global inpatient urinary tract
isolates of eswcherichia coli: results fromthe study formonitoring
antimicrobial resistance trends (SMART) program: 2009-2010.
Diagn Microbiol Infect Dis
2011;70(4);507-511.
21.
Zhanel GG, Karlowsky JA, Harding GKM et al. A Canadian
national surveillance study of urinary tract isolates from
outpatients: comparison of the activities of trimethoprim-
sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and
ciprofloxacin.
Antimicrob Agents Chemother
2000;44(4):1089-1092.
22.
Richards DA, Toop LJ, Chambers ST et al.Antibiotic resistance in
uncomplicatedurinary tract infection: problemswith interpreting
cumulative resistance rates from local community laboratories.
N Z Med J
2002;115(1146):12-14.
